The drugmaker’s stock is moving higher this morning in response to the news that its inhaledParkinson’s disease drug, CVT-301, hit the mark in a late-stage trial. According to the press release, patients receiving CVT-301 exhibited astatistically significant improvement in motor function whenexperiencing off periods compared to those taking a placebo.